Utama › Kanser Payudara Triple-Negatif › Illinois
Kajian klinikal Kanser Payudara Triple-Negatif di Illinois
20 kajian untuk Kanser Payudara Triple-Negatif sedang mencari peserta di lokasi di Illinois.
Bandar di Illinois
Teks kajian rasmi (Bahasa Inggeris)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Chicago Hospital, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06465069PRE-ISPY Phase I/II Oncology Platform Program
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
- UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
- UChicago Medicine Orland Park, Orland Park
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT05868226Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Illinois Cancer Specialists (ICS) ( Site 8010), Arlington Heights
- Southern Illinois Hospital Services ( Site 9547), Carterville
- Orchard Healthcare Research Inc. ( Site 0014), Skokie
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- University of Illinois Cancer Center ( Site 0044), Chicago
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06841354Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Northwestern University Feinberg School of Medicine, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05983432Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Northwestern Medicine, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
- dan 3 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT05633654Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Southern Illinois Hospital Services, Carbondale
- Cancer Care Specialist of Illinois, O'Fallon
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 99 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07211178SMP-3124LP in Adults With Advanced Solid Tumors
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT06526819A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 0280, Chicago
- Decatur Memorial Hospital, Decatur
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT06926868A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Northwestern University, Chicago
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT05005403A Study of LY4175408 in Participants With Advanced Cancer
- The University of Chicago Medical Center (UCMC), Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT07046923Study of XB010 in Subjects With Solid Tumors
- University of Chicago Medical Center, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT06545331A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Northwestern Memorial Hospital, Chicago
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT04300556I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Chicago, Chicago
- Loyola University, Maywood
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT01042379Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- University of Chicago Medical Center, Chicago
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Apr 2026 · NCT04468061A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- UChicago Medicine Comprehensive Cancer Center, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06908928A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Kellogg Cancer Center, Evanston
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Nov 2025 · NCT05902988A Study of NX-1607 in Adults With Advanced Malignancies
- University of Chicago, Chicago
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT05107674CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Illinois Cancer Care, Peoria
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Wanita · Dikemas kini 7 Jan 2025 · NCT06230185Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.